- Poster presentation
- Open Access
Phase III, randomized, open-label study of durvalumab (MEDI4736) monotherapy, or durvalumab + tremelimumab, versus standard of care (SoC), in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): eagle
© Ferris et al. 2015
- Published: 4 November 2015
We’re sorry, something doesn't seem to be working properly.
Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.
- Inhibitory Immune Checkpoint
- Synergistic Antitumor Effect
- High Mutational Load
- Preliminary Antitumor Activity
Patients with R/M SCCHN have a poor prognosis, and current therapies used after failure of first-line platinum-based chemotherapy provide transient, limited benefit. SCCHN tumors are highly immunosuppressive and evade immune detection by exploiting inhibitory immune checkpoints such as the programmed cell death ligand-1 (PD-L1)/programmed cell death-1 (PD-1) axis. High mutational load and their relationship to human papillomavirus (HPV) infection may make these tumors amenable to immunotherapy. Durvalumab is a selective, human IgG1 mAb that blocks binding of PD-L1: to PD-1 (IC50 0.1 nM) and CD80 (IC50 0.04 nM). Tremelimumab is a selective human IgG2 mAb inhibitor of cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4). The PD-1 and CTLA-4 pathways are non-redundant and targeting both induces synergistic antitumor effects, according to preclinical data, and was found to be active and tolerable in a Phase Ib study in patients with NSCLC (NCT02000947). Durvalumab monotherapy has also shown preliminary antitumor activity in a Phase I/II study in patients with solid tumors, including a SCCHN cohort (NCT01693562). In a comprehensive clinical development program of durvalumab in SCCHN, the Phase III EAGLE study (NCT02369874) will investigate the efficacy and safety of durvalumab as monotherapy or in combination with tremelimumab versus SoC.
ClinicalTrials.gov identifier NCT02369874.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.